BIO-RAD LABORATORIES, INC.
BIOBio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
Drugs in Pipeline
108
Phase 3 Programs
40
Upcoming Catalysts
19
Next Catalyst
Mar 15, 2026
25dMarket Overview
Stock performance and key metrics
19 upcoming, 1 past
Jointstem
Knee Osteoarthritis
DTP/HB/Hib Vaccine
Healthy
hMG subcutaneous injection
Infertility (IVF Patients)
Roxadustat
Anemia Associated With End Stage Renal Disease (ESRD)
Vicinium
Bladder Cancer
Tadekinig alfa
XIAP Deficiency
CKDB-501A
Glabellar Lines
MCS-2 15 mg/day
Lower Urinary Tract Symptoms
BAT2306
Plaque Psoriasis
AB103 0.5 mg/kg
Necrotizing Soft Tissue Infections
Erythropoietin alfa
Anemia of Chronic Kidney Disease
SARS-CoV-2 vaccine (inactivated)
SARS-CoV2 Infection
BAT1806
Rheumatoid Arthritis
teplizumab
Type 1 Diabetes Mellitus
FDA018-ADC
Triple Negative Breast Cancer
Avacincaptad Pegol
Geographic Atrophy
OCA
PBC
COVID-19 Protein Subunit Recombinant Vaccine
COVID-19
Antiscorpion venom serum(AScVS).
Scorpion Envenomation
Epoetin Alfa
Anemia in End Stage Renal Disease
TBI-1301
Synovial Sarcoma
Pentavalen
Healthy
MCS-2
Lower Urinary Tract Symptoms
Cyclophosphamide
Synovial Sarcomas
Vaccine
Healthy
Buntanetap/Posiphen
Alzheimer Disease
PJ009
Short Bowel Syndrome
JMT101
Locally Advanced or Metastatic Non-squamous NSCLC
N1539
Pain, Post-operative
BAT2206
Plaque Psoriasis
KN026
Early or Locally Advanced HER2-positive Breast Cancer
Vi-DT Typhoid Conjugate Vaccine
Vaccine
FG-4592
Anemia
BAT5906 injection
Neovascular (Wet) Age-related Macular Degeneration
VBI-S
Septic Shock
Recombinant Humanized Bispecific antibody against HER2，KN026
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
CDFR0612
Colonoscopy Preparation
Haporine-S
Dry Eye Syndromes
Iclaprim
Skin Structures and Soft Tissue Infections
Recombinant Hepatitis B vaccine
Immunogenicity
NH002 (Perflutren Lipid Microspheres) Injectable Suspension
Cardiac Disease
Recombinant Human Proteoglycan 4
Sjögren's Syndrome
tOPV pilot batch
Healthy
SARS-CoV-2 Subunit Recombinant Protein Vaccine
COVID-19
CAM-101 10%
Dry Eye
PRX302
Benign Prostatic Hyperplasia
rhPRG4 450ug/ml
Ocular Graft Versus Host Disease
Aminolaevulinic acid photodynamic therapy
Cervical Persistent High Risk HPV Infection
H002
Non-small Cell Lung Cancer
2.5mg of BAT5906
Diabetic Macular Edema
Verekitug (UPB-101)
Severe Asthma
QLS-101ophthalmic solution 1%
Sturge-Weber Syndrome (SWS)
PolyPEPI1018
Colorectal Cancer Metastatic
TOUR006 - 20 MG
Thyroid Eye Disease
SB1518
Hodgkin Lymphoma
AVB-114
Perianal Fistula
KAN-101
Celiac Disease
BAT8010 for Injection
Advanced Solid Tumors
AXER-204
Chronic Spinal Cord Injury
U32 CAR-T
Acute Myeloid Leukaemia
HLA-G-CAR.BiTE allogeneic γδ T cells
Solid Tumor
autologous dendritic cells
GBM
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection
Parkinson Disease (PD)
TER-101
Atopic Dermatitis
TRIV-509
Atopic Dermatitis
BG1805
Leukemia, Myeloid, Acute
JMT108
Unresectable Locally Advanced or Metastatic Melanoma
BXP154
Wound Bleeding
BGM0504
Overweight or Obesity
SA53-OS (phase 1)
Solid Tumor
PolyPEPI1018 CRC Vaccine
Colorectal Cancer
Monoclonal antibody BAT6026
Dermatitis, Atopic
'SMT-NK' Inj (allogeneic Natural Killer cell)
Biliary Tract Cancer
H002 capsule
Non-small Cell Lung Cancer
LEU011
Tumor, Solid
Allogeneic umbilical cord mesenchymal stem cells
ST Elevation Myocardial Infarction
QLS-111 Ophthalmic Solution (0.015%)
Non-proliferative Diabetic Retinopathy (NPDR)
Bone marrow mesenchymal stem cells
Osteoarthritis, Knee
pegylated recombinant human arginase
Hepatocellular Carcinoma
Vi-DT Vaccine
Safety Issues
INX-315
Breast Cancer
Eprotirome
Primary Hypercholesterolemia
TBI-1501
Lymphoblastic Leukemia, Acute Adult
ADSTEM Inj.
Atopic Dermatitis
BAT8008 injection
Advanced Solid Tumors
TOUR006 - 50 MG
Chronic Kidney Diseases
CGB-500 with 0.5% tofacitinib
Atopic Dermatitis (AD)
OCE-205
Cirrhosis
Tadekinig alfa (recombinant human IL-18 binding protein)
Still's Disease, Adult-Onset
Endostar(Recombinant Human Endostatin Injection)
Advanced Non-small Cell Lung Cancer
AB103
Necrotizing Soft Tissue Infections
CD7 CAR-T
T-Cell Acute Lymphocytic Leukemia
QLS-111, 0.015%
Open-angle Glaucoma (OAG)
DTP/HB and Hib vaccine
Healthy
DR-01
LGLL - Large Granular Lymphocytic Leukemia
DEX-IN
Pain
conventional therapy plus low dose hUC-MSCs treatment
Liver Cirrhosis
Intranasal Dexmedetomidine
Pain, Post-operative
CABA-201
Systemic Lupus Erythematosus
Pegylated Recombinant Human Arginase I
Neoplasm
PACOX
Hepatocellular Carcinoma
TBI-1401(HF10)
Melanoma Stage III
LB1410
Solid Tumor
GB002 (seralutinib)
Pulmonary Arterial Hypertension
VRB-101
Obesity
Brequinar
COVID-19 Infection
VBC103
Participants With Advanced Solid Tumor Malignancies
JIN-A02
EGFR Mutant Advanced Non-small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Jointstem | Phase 3 | Knee Osteoarthritis | - | - |
DTP/HB/Hib Vaccine | Phase 3 | Healthy | - | - |
hMG subcutaneous injection | Phase 3 | Infertility (IVF Patients) | - | - |
Roxadustat | Phase 3 | Anemia Associated With End Stage Renal Disease (ESRD) | - | - |
Vicinium | Phase 3 | Bladder Cancer | - | - |
Tadekinig alfa | Phase 3 | XIAP Deficiency | - | - |
CKDB-501A | Phase 3 | Glabellar Lines | - | - |
MCS-2 15 mg/day | Phase 3 | Lower Urinary Tract Symptoms | - | - |
BAT2306 | Phase 3 | Plaque Psoriasis | - | - |
AB103 0.5 mg/kg | Phase 3 | Necrotizing Soft Tissue Infections | - | - |
Erythropoietin alfa | Phase 3 | Anemia of Chronic Kidney Disease | - | - |
SARS-CoV-2 vaccine (inactivated) | Phase 3 | SARS-CoV2 Infection | - | - |
BAT1806 | Phase 3 | Rheumatoid Arthritis | - | - |
teplizumab | Phase 3 | Type 1 Diabetes Mellitus | - | - |
FDA018-ADC | Phase 3 | Triple Negative Breast Cancer | - | - |
Avacincaptad Pegol | Phase 3 | Geographic Atrophy | - | - |
OCA | Phase 3 | PBC | - | - |
COVID-19 Protein Subunit Recombinant Vaccine | Phase 3 | COVID-19 | - | - |
Antiscorpion venom serum(AScVS). | Phase 3 | Scorpion Envenomation | - | - |
Epoetin Alfa | Phase 3 | Anemia in End Stage Renal Disease | - | - |
TBI-1301 | Phase 3 | Synovial Sarcoma | - | - |
Pentavalen | Phase 3 | Healthy | - | - |
MCS-2 | Phase 3 | Lower Urinary Tract Symptoms | - | - |
Cyclophosphamide | Phase 3 | Synovial Sarcomas | - | - |
Vaccine | Phase 3 | Healthy | - | - |
Buntanetap/Posiphen | Phase 3 | Alzheimer Disease | - | - |
PJ009 | Phase 3 | Short Bowel Syndrome | - | - |
JMT101 | Phase 3 | Locally Advanced or Metastatic Non-squamous NSCLC | - | - |
N1539 | Phase 3 | Pain, Post-operative | - | - |
BAT2206 | Phase 3 | Plaque Psoriasis | - | - |
KN026 | Phase 3 | Early or Locally Advanced HER2-positive Breast Cancer | - | - |
Vi-DT Typhoid Conjugate Vaccine | Phase 3 | Vaccine | - | - |
FG-4592 | Phase 3 | Anemia | - | - |
BAT5906 injection | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration | - | - |
VBI-S | Phase 3 | Septic Shock | - | - |
Recombinant Humanized Bispecific antibody against HER2，KN026 | Phase 3 | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | - | - |
CDFR0612 | Phase 3 | Colonoscopy Preparation | - | - |
Haporine-S | Phase 3 | Dry Eye Syndromes | - | - |
Iclaprim | Phase 3 | Skin Structures and Soft Tissue Infections | - | - |
Recombinant Hepatitis B vaccine | Phase 3 | Immunogenicity | - | - |
NH002 (Perflutren Lipid Microspheres) Injectable Suspension | Phase 2 | Cardiac Disease | - | - |
Recombinant Human Proteoglycan 4 | Phase 2 | Sjögren's Syndrome | - | - |
tOPV pilot batch | Phase 2 | Healthy | - | - |
SARS-CoV-2 Subunit Recombinant Protein Vaccine | Phase 2 | COVID-19 | - | - |
CAM-101 10% | Phase 2 | Dry Eye | - | - |
PRX302 | Phase 2 | Benign Prostatic Hyperplasia | - | - |
rhPRG4 450ug/ml | Phase 2 | Ocular Graft Versus Host Disease | - | - |
Aminolaevulinic acid photodynamic therapy | Phase 2 | Cervical Persistent High Risk HPV Infection | - | - |
H002 | Phase 2 | Non-small Cell Lung Cancer | - | - |
2.5mg of BAT5906 | Phase 2 | Diabetic Macular Edema | - | - |
Verekitug (UPB-101) | Phase 2 | Severe Asthma | - | - |
QLS-101ophthalmic solution 1% | Phase 2 | Sturge-Weber Syndrome (SWS) | - | - |
PolyPEPI1018 | Phase 2 | Colorectal Cancer Metastatic | - | - |
TOUR006 - 20 MG | Phase 2 | Thyroid Eye Disease | - | - |
SB1518 | Phase 2 | Hodgkin Lymphoma | - | - |
AVB-114 | Phase 2 | Perianal Fistula | - | - |
KAN-101 | Phase 2 | Celiac Disease | - | - |
BAT8010 for Injection | Phase 2 | Advanced Solid Tumors | - | - |
AXER-204 | Phase 2 | Chronic Spinal Cord Injury | - | - |
U32 CAR-T | Phase 2 | Acute Myeloid Leukaemia | - | - |
HLA-G-CAR.BiTE allogeneic γδ T cells | Phase 2 | Solid Tumor | - | - |
autologous dendritic cells | Phase 2 | GBM | - | - |
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection | Phase 2 | Parkinson Disease (PD) | - | - |
TER-101 | Phase 2 | Atopic Dermatitis | - | - |
TRIV-509 | Phase 2 | Atopic Dermatitis | - | - |
BG1805 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
JMT108 | Phase 2 | Unresectable Locally Advanced or Metastatic Melanoma | - | - |
BXP154 | Phase 2 | Wound Bleeding | - | - |
BGM0504 | Phase 2 | Overweight or Obesity | - | - |
SA53-OS (phase 1) | Phase 2 | Solid Tumor | - | - |
PolyPEPI1018 CRC Vaccine | Phase 2 | Colorectal Cancer | - | - |
Monoclonal antibody BAT6026 | Phase 2 | Dermatitis, Atopic | - | - |
'SMT-NK' Inj (allogeneic Natural Killer cell) | Phase 2 | Biliary Tract Cancer | - | - |
H002 capsule | Phase 2 | Non-small Cell Lung Cancer | - | - |
LEU011 | Phase 2 | Tumor, Solid | - | - |
Allogeneic umbilical cord mesenchymal stem cells | Phase 2 | ST Elevation Myocardial Infarction | - | - |
QLS-111 Ophthalmic Solution (0.015%) | Phase 2 | Non-proliferative Diabetic Retinopathy (NPDR) | - | - |
Bone marrow mesenchymal stem cells | Phase 2 | Osteoarthritis, Knee | - | - |
pegylated recombinant human arginase | Phase 2 | Hepatocellular Carcinoma | - | - |
Vi-DT Vaccine | Phase 2 | Safety Issues | - | - |
INX-315 | Phase 2 | Breast Cancer | - | - |
Eprotirome | Phase 2 | Primary Hypercholesterolemia | - | - |
TBI-1501 | Phase 2 | Lymphoblastic Leukemia, Acute Adult | - | - |
ADSTEM Inj. | Phase 2 | Atopic Dermatitis | - | - |
BAT8008 injection | Phase 2 | Advanced Solid Tumors | - | - |
TOUR006 - 50 MG | Phase 2 | Chronic Kidney Diseases | - | - |
CGB-500 with 0.5% tofacitinib | Phase 2 | Atopic Dermatitis (AD) | - | - |
OCE-205 | Phase 2 | Cirrhosis | - | - |
Tadekinig alfa (recombinant human IL-18 binding protein) | Phase 2 | Still's Disease, Adult-Onset | - | - |
Endostar(Recombinant Human Endostatin Injection) | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |
AB103 | Phase 2 | Necrotizing Soft Tissue Infections | - | - |
CD7 CAR-T | Phase 2 | T-Cell Acute Lymphocytic Leukemia | - | - |
QLS-111, 0.015% | Phase 2 | Open-angle Glaucoma (OAG) | - | - |
DTP/HB and Hib vaccine | Phase 2 | Healthy | - | - |
DR-01 | Phase 2 | LGLL - Large Granular Lymphocytic Leukemia | - | - |
DEX-IN | Phase 2 | Pain | - | - |
conventional therapy plus low dose hUC-MSCs treatment | Phase 2 | Liver Cirrhosis | - | - |
Intranasal Dexmedetomidine | Phase 2 | Pain, Post-operative | - | - |
CABA-201 | Phase 2 | Systemic Lupus Erythematosus | - | - |
Pegylated Recombinant Human Arginase I | Phase 2 | Neoplasm | - | - |
PACOX | Phase 2 | Hepatocellular Carcinoma | - | - |
TBI-1401(HF10) | Phase 2 | Melanoma Stage III | - | - |
LB1410 | Phase 2 | Solid Tumor | - | - |
GB002 (seralutinib) | Phase 2 | Pulmonary Arterial Hypertension | - | - |
VRB-101 | Phase 2 | Obesity | - | - |
Brequinar | Phase 2 | COVID-19 Infection | - | - |
VBC103 | Phase 2 | Participants With Advanced Solid Tumor Malignancies | - | - |
JIN-A02 | Phase 2 | EGFR Mutant Advanced Non-small Cell Lung Cancer | - | - |